Humanin
WellnessAlso known as: HN, Humanin G (HNG), MTRNR2L8 peptide
Emerging ResearchWhat is Humanin?
A 21-amino acid peptide encoded in the mitochondrial genome, discovered in 2001 as a neuroprotective factor. Humanin levels decline sharply with age and in Alzheimer's disease. Emerging research links it to longevity, insulin sensitivity, and cytoprotection — though human data remains preliminary.
How it works
Encoded by the 16S rRNA region of mitochondrial DNA. Binds to gp130 (IL-6 signal transducer), FPRL-1, and an intracellular IGFBP-3/PAPP-A complex. Key mechanisms: inhibits Bax-mediated apoptosis, activates STAT3 signaling for cell survival, and potently enhances insulin receptor sensitivity. A potent analog, Humanin G (HNG), replaces Ser-14 with Gly for 100–1000× greater bioactivity.
What marketers claim
- ▸reverses Alzheimer's disease
- ▸dramatically extends lifespan
- ▸replaces metformin for insulin sensitivity
- ▸no side effects at any dose
What evidence supports
- ✓plasma Humanin significantly lower in Alzheimer's patients vs healthy age-matched controls
- ✓neuroprotection against Aβ toxicity in cell culture and mouse models
- ✓extends lifespan in C. elegans; improves healthspan markers in mice
- ✓improves insulin sensitivity in insulin-resistant mouse models
- ✓offspring of centenarians have higher circulating Humanin levels (UCLA, 2012)
Research evidence
Key studies on Humanin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Humanin prevents neuronal death induced by amyloid beta peptide in vitro
Finding: Original discovery paper: nanomolar concentrations of Humanin completely blocked Aβ-induced apoptosis in neuronal cell cultures, establishing its neuroprotective identity.
Limitation: In vitro only; concentrations used may not be achievable in vivo without exogenous administration.
Circulating Humanin levels are associated with cognitive function and Alzheimer's disease
Finding: Plasma Humanin significantly lower in MCI and AD patients compared with age-matched cognitively normal controls; inversely correlated with disease severity on standard cognitive assessments.
Limitation: Observational cross-sectional design; cannot establish whether low Humanin causes cognitive decline or is a consequence of neurodegeneration.
Humanin and MOTS-c as regulators of metabolism and longevity
Finding: Comprehensive review documenting longevity mechanisms of mitochondria-derived peptides across model organisms, including lifespan extension in C. elegans and improved insulin sensitivity in rodents.
Limitation: Review article summarizing mostly animal and in vitro data; human translational evidence remains very limited.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Unknown
No human clinical timeline exists. Animal models show acute neuroprotective effects within hours of administration; chronic metabolic benefits emerge over weeks in rodent studies. Human pharmacokinetics and optimal dosing are entirely undefined.
Safety notes & concerns
Full safety guide →- ⚠no completed human clinical trials for longevity or cognitive indications
- ⚠no FDA-approved or commercially available Humanin product
- ⚠most evidence is in vitro or animal/invertebrate — may not translate to humans
- ⚠optimal route, dose, and frequency in humans unknown
- ⚠long-term human safety data absent
Pairs well with
Use caution with
Frequently asked questions
What makes Humanin special among longevity peptides?
Humanin is a mitochondria-derived peptide (MDP) — one of the few peptides encoded in mitochondrial DNA rather than nuclear DNA. Its association with exceptional longevity (higher circulating levels in centenarian offspring vs age-matched controls) is intriguing, but this is correlational data only. It remains one of the most scientifically compelling longevity peptides precisely because its natural decline with aging mirrors age-related disease progression.
Is Humanin available as a supplement?
Not meaningfully. As a peptide it is degraded by gastrointestinal proteases and cannot be absorbed intact orally. It would require injection to reach systemic circulation. No injectable Humanin product has completed clinical trials or received regulatory approval. Any oral supplement claiming to deliver active Humanin is not supported by basic pharmacokinetics.
Related wellness peptides
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
understanding as a cautionary example of peptide marketing vs evidence
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Humanin
Last updated: 2026-06-10
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.